OSR Holdings’ subsidiary Vaximm completed analysis from two VXM01 trials in recurrent glioblastoma and plans a peer-reviewed submission in the coming months.
Vaximm flagged encouraging cross-indication results, with top-line updates expected soon on VXM01’s development path.
VXM01 was reported safe and well tolerated as monotherapy or in combination, with no dose-limiting toxicities or high-grade treatment-related events.
Analyses showed immune activation against VEGFR-2, with dose-dependent signals and biomarker support consistent with the proposed mechanism.
OSRH•
